Standalone Financial Results, Limited Review Report for June 30, 2016
Jagsonpal Pharmaceuticals Ltd has informed BSE about : 1. Standalone Financial Results for the period ended June 30, 20162. Standalone Limited Review for the period ended June 30, 2016 Shareholding for the Period Ended March 31, 2016
Jagsonpal Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2016. For more details, kindly Click here Board Meeting Intimation for Results & Closure of Trading Window
Jagsonpal Pharmaceuticals Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on August 12, 2016, to consider, approve and take on record the Un-audited Financial Results (provisional) of the Company for the quarter ended June 30, 2016.Pursuant to the Code of Conduct adopted by the Company under SEBI (Prohibition of Insider Trading) Regulations, 2015, the Trading Window will remain closed for dealing... Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended June 30, 2016
Jagsonpal Pharmaceuticals Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended June 30, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Shareholding for the Period Ended June 30, 2016
Jagsonpal Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2016. For more details, kindly Click here Board recommends Dividend
Jagsonpal Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 30, 2016, has recommended a dividend at the rate of Rs. 0.10 per equity share of Rs. 5/- each, The dividend, if approved by the shareholders in the ensuing Annual General meeting scheduled to be held on September 30, 2016.The Board Meeting commenced at 12.00 noon and concluded at 3.40 p.m. Standalone Financial Results, Form A, Auditors Report for March 31, 2016
Jagsonpal Pharmaceuticals Ltd has informed BSE about : 1. Standalone Financial Results for the period ended March 31, 20162. Standalone Form A for the period ended March 31, 20163. Standalone Auditors Report for the period ended March 31, 2016 Board to consider Dividend
Jagsonpal Pharmaceuticals Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on May 30, 2016, inter alia, to consider the following:1. To Consider and Approve the Audited financial results for the quarter/year ended March 31, 2016.2. To Recommend dividend, if any, for the year ended March 31, 2016.... Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended March 31, 2016
Jagsonpal Pharmaceuticals Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended March 31, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.